Market closed · Next open: Monday 9:30 AM ET
Last update: Nov 20, 2026, 6:14 PM ET
Globus Medical, Inc.
$66.89▼ 2.49% today
Market Closed

Why Globus Medical, Inc. (GMED) stock moved

No significant move on Nov 20, 2026 (−2.5%, close-to-close). Latest notable session: Nov 19, 2026.

Latest session▼ 2.7% · Nov 19, 2026 close

Why Globus Medical, Inc. (GMED) fell 2.7% on November 19, 2026

Globus Medical, Inc. (GMED) fell 2.7% on November 19, 2026, closing at $68.60 versus $70.53 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The decline coincided with the company presenting at the Jefferies Global Healthcare Conference, though no specific announcements or guidance changes were disclosed. Source: FMP price data; BestStocks detection.

Updated
Prior close
$70.53
Nov 19, 2026 close
$68.60
Change (close-to-close)
−$1.93
−2.74%
As first detected · Nov 19, 2026, 4:46 PM ET

Globus Medical, Inc. (GMED) moved -2.38% from $70.27 to $68.60 on November 19, 2026. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The decline coincided with the company presenting at the Jefferies Global Healthcare Conference, though no specific announcements or guidance changes were disclosed.

What to watch next: Earnings on 2027-02-23 against consensus EPS estimate of $1.30.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved GMED

  1. −4.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  2. +7.5%On November 5, the company reported Q3 non-GAAP EPS of $1.23, beating consensus, but lowered full-year 2026 revenue guidance to $3.09 billion due to softer Nevro sales and delayed spine product launches.
  3. −12.8%Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). Read the November 6, 2026 analysis →
  4. −6.5%Volume was 2.5× the 5-day average.
  5. +9.4%The move followed news that GMED is shifting its robot leasing strategy to prioritize recurring implant revenue over upfront capital sales, and Wall Street analysts set a consensus price target implying 30.52% upside potential.
  6. −5.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  7. +3.8%On the same day, a law firm announced a shareholder investigation into GMED officers and directors for potential fiduciary duty breaches involving self-dealing.
  8. +4.4%As value-focused investors stepped in following analyst commentary highlighting GMED as a "Strong Value Stock" trading well below its $103.23 fair value estimate (per Zacks and Yahoo Finance).
  9. −2.7%We checked news, earnings, analyst updates, filings, and corporate actions.
  10. +3.3%The move coincided with the company showcasing SCRIPT patient-specific implants and a new XLIF prone procedural solution at NASS 2026.
  11. −4.2%Following analyst caution and broader sector headwinds in the medical device market, according to MarketBeat.
  12. −3.1%Following a broader selloff despite the company beating consensus estimates on both top and bottom lines, according to Seeking Alpha.

Globus Medical, Inc. (GMED) shares fell 2.5% to $66.89 as of November 22, 2026, a modest decline from the prior close of $68.60. BestStocks flagged the session as a major change for GMED. The move is tied to price move up. Below, we break down what changed for GMED, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

GMED fell 2.5% to $66.89

GMED fell 2.5% in its latest session, moving from $68.60 to $66.89.

Material / EarningsLow confidence
Rel. volume
1.0×
Below Avg
Vs peers
—
No comparable peers
Market cap
$8.9B
New York Stock Exchange
Analyst target
$88
+30.8% vs price
Price chart
Oct 22 – Nov 20
NEVENEF$67$77$87Oct 22Oct 29Nov 6Nov 13Nov 20
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Globus Medical, Inc. investors

For Globus Medical, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Globus Medical, Inc. (GMED) moved +5.55% from $81.62 to $86.15 on 2026-08-10, reaching a new 30-day high on modestly elevated volume (1.7x the 5-day average); Positive price momentum. Weighing against that: Material negative event; Negative session, down 2.5%. Wall Street's consensus price target sits at $87.50, implying +30.8% upside from $66.89. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (46/100). With earnings roughly 93 days out, the next report is the most likely near-term test of the move.

GMED price reaction

GMED last traded at $66.89, down $1.71 (-2.49%) from the previous close of $68.60. The session traded on 1.0× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $66.89 and $87.10, and it currently sits about 0% of the way up that band.

Bullish and bearish analyst opinions on Globus Medical, Inc. (GMED)

The consensus analyst price target on Globus Medical, Inc. (GMED) is $87.50, 30.8% above the recent $66.89. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 1 downgrade. Here is how the bullish and bearish cases on GMED line up.

The bullish case

  • Wall Street's consensus price target of $87.50 implies +30.8% upside from $66.89.
  • The Street's most bullish target is $100.00 (+49.5%).
  • Globus Medical, Inc. (GMED) moved +5.55% from $81.62 to $86.15 on 2026-08-10, reaching a new 30-day high on modestly elevated volume (1.7x the 5-day average).
  • Positive price momentum.

The bearish case

  • 1 analyst downgrade in the past 90 days, most recently BMO Capital to Market Perform (2026-11-06).
  • Material negative event.
  • Negative session, down 2.5%.
  • Globus Medical, Inc. (GMED) moved -6.55% from $88.12 to $82.35 on 2026-08-07.
  • GMED fell 3.38% to $76.34 intraday on volume 1.24x normal for this time of session.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $88+30.8%
= 5 maintains↓ 1 downgrades
Truist Securities maintained Buy · 2026-11-09
SEC filings watch
8-K2026-11-05
Material event — review for impact
high
10-Q2026-11-05
Quarterly financial results
medium
8-K2026-08-06
Material event — review for impact
high
10-Q2026-08-06
Quarterly financial results
medium
Peer context
GMED-2.5%

Previous notable changes for GMED

News2026-11-09+7.5%
Globus Medical to present at Jefferies Global Healthcare Conference in London.
Valuation2026-11-06-12.8%via investing.com ↗
Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). The selloff was compounded by a 25.7% drop in Nevro sales, slower sales rep productivity, and delayed spine product launches now pushed to 2027, plus BMO Capital Markets downgrading GMED from Outperform to Market Perform with a price target cut from $94 to $78. Stock fell 11.15% to $72.36 on elevated volume of 5.1 million shares (6.08x historical average for this time of session).
Material / Earnings2026-11-05-6.5%
Globus Medical, Inc. (GMED) moved -7.08% from $87.73 to $81.52 on 2026-11-05, the same day it reported Q3 FY2026 earnings that beat consensus EPS by 2.50% ($1.23 vs $1.20 estimate). Volume was 2.5× the 5-day average.
News2026-11-05-6.5%
Globus Medical increased share repurchase authorization by $500 million amid Q3 2026 results.

In-depth GMED event analyses

Permanent, dated analyses of GMED's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2027-02-23 (est.)
in 93 days
Earnings Release
2027-02-23
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about GMED

Why did Globus Medical, Inc. (GMED) stock move?

Globus Medical, Inc. (GMED) fell 2.7% on November 19, 2026, closing at $68.60 versus $70.53 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The decline coincided with the company presenting at the Jefferies Global Healthcare Conference, though no specific announcements or guidance changes were disclosed. Source: FMP price data; BestStocks detection.

How much did GMED stock fall?

GMED lost 2.49% ($1.71) versus the prior close of $68.60, last trading at $66.89 on 1.0× average volume.

When is Globus Medical, Inc.'s next earnings date?

GMED's next earnings report is estimated for 2027-02-23 — about 93 days away.

What is the analyst price target for GMED?

The consensus analyst price target for GMED is $87.50, about 30.8% above the current $66.89. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 1 downgrade.

How BestStocks tracks GMED

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for GMED, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.